About sol gel technologies ltd - SLGL
Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.
SLGL At a Glance
Sol-Gel Technologies Ltd.
Weizmann Science Park
Ness Ziona, Tel Aviv 74036
| Phone | 972-8-931-3433 | Revenue | 19.39M | |
| Industry | Pharmaceuticals: Major | Net Income | -6,127,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 68.036% | |
| Fiscal Year-end | 12 / 2026 | Employees | 28 | |
| View SEC Filings |
SLGL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 6.055 |
| Price to Book Ratio | 5.147 |
| Price to Cash Flow Ratio | 364.59 |
| Enterprise Value to EBITDA | -12.614 |
| Enterprise Value to Sales | 4.868 |
| Total Debt to Enterprise Value | 0.01 |
SLGL Efficiency
| Revenue/Employee | 692,428.571 |
| Income Per Employee | -218,821.429 |
| Receivables Turnover | 9.852 |
| Total Asset Turnover | 0.59 |
SLGL Liquidity
| Current Ratio | 4.371 |
| Quick Ratio | 4.371 |
| Cash Ratio | 3.889 |
SLGL Profitability
| Gross Margin | 99.438 |
| Operating Margin | -39.158 |
| Pretax Margin | -31.602 |
| Net Margin | -31.602 |
| Return on Assets | -18.634 |
| Return on Equity | -23.72 |
| Return on Total Capital | -25.742 |
| Return on Invested Capital | -23.105 |
SLGL Capital Structure
| Total Debt to Total Equity | 4.344 |
| Total Debt to Total Capital | 4.164 |
| Total Debt to Total Assets | 3.312 |
| Long-Term Debt to Equity | 2.174 |
| Long-Term Debt to Total Capital | 2.084 |